AMLo Biosciences at EADO 2024: new biomarker data to improve melanoma prognostic understanding AMLo Biosciences is pleased to announce its involvement at the 20th European Association of Dermato-Oncology (EADO) Congress being held in Paris, France, 4–6 April 2024,...
New proof-of-concept data published for biomarkers to identify cutaneous squamous cell carcinomas at high risk of progression AMLo Biosciences announces the recent publication of a proof-of-concept study for biomarkers AMBRA1 and SQSTM1 in the identification of poorly...
AMLo Biosciences at AAD 2024: Advancing melanoma diagnostics with prognostic insight As the American Association of Dermatology (AAD) 2024 Conference draws near, AMLo Biosciences is thrilled to announce that 5 members of the US and UK teams are attending to share...
AMLo Biosciences granted AMBLor® patent in Brazil widening the exclusive usage of the melanoma diagnostic technology A patent grant has recently been awarded to AMLo Biosciences for their prognostic biomarker technology, AMBLor®, in Brazil. AMBLor® is an innovative...
New data published in the BJD pivotal in validating prognostic biomarker technology AMBLor® AMLo Biosciences are delighted about the recent publication of a large-cohort international validation study, confirming that the combined biomarkers, AMBRA1 and loricrin...
Avero Diagnostics and AMLo Biosciences publish pivotal data for diagnostic biomarker technology AMBLor® in identifying melanomas at low risk of metastasis Avero Diagnostics (Bellingham, WA and Irving, TX) and AMLo Biosciences Ltd (Newcastle upon Tyne, UK) announce the...
AMLo Biosciences Limited is a company registered in England and Wales. Company # 11004534
Trading address: Newcastle University, The Medical School, Framlington Place, Newcastle upon Tyne, NE2 4HH, United Kingdom
Registered address: c/o RMT Accountants & Business Advisors Ltd, Gosforth Park Avenue, Newcastle upon Tyne, NE12 8EG, United Kingdom
VAT # 285288950
Sign up for our newsletter